Blue Water Ventures International, Inc. BWVI
Set alert
At close · Oct 30
- YTD
- +600.00%
- 1 year
- +133.33%
- Open
- 0.0003
- Prev close
- 0.0007
- Mkt cap
- 211.95K
- Vol
- 50.00K
- Avg vol
- 8.34K
- EPS
- -0.02
- P/E
- -0.03
More statistics
- Low
- 0.0003
- High
- 0.0007
News
2 years ago accesswire.com
Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
MIAMI, FL / ACCESSWIRE / May 16, 2024 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for…
2 years ago accesswire.com
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
The distress in the psychedelic space contributed to the Company's challenges. The inability of the Company to undertake certain corporate actions (name and symbol change etc.
2 years ago accesswire.com
Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
MIAMI, FL / ACCESSWIRE / December 12, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge…
3 years ago accesswire.com
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
Company's novel NeuroDirectTM topical ketamine formulation to treat PTSD shown to be safe and well-tolerated in first cohort of Phase I trial. MIAMI, FL / ACCESSWIRE / August 10, 2023 /…
3 years ago accesswire.com
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Multi-year PCAOB audited financials completed Company on the path to become fully SEC reporting Future corporate action with name and symbol change MIAMI, FL / ACCESSWIRE / August 1, 2023 /…
3 years ago accesswire.com
First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder through the company's NeuroDirect™ delivery system.…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Stocks That Hit 52-Week Lows On Friday